Statements (14)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:alsoKnownAs |
Bentracimab
|
| gptkbp:clinicalTrialPhase |
Phase 3
|
| gptkbp:developedBy |
PhaseBio Pharmaceuticals
|
| https://www.w3.org/2000/01/rdf-schema#label |
BT-200
|
| gptkbp:indication |
reversal of antiplatelet effects in patients treated with ticagrelor
|
| gptkbp:intendedUse |
antiplatelet reversal agent
|
| gptkbp:mechanismOfAction |
binds ticagrelor and its active metabolite
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:status |
investigational
|
| gptkbp:target |
gptkb:ticagrelor
|
| gptkbp:bfsParent |
gptkb:Epson_Moverio
gptkb:Epson_Moverio_smart_glasses |
| gptkbp:bfsLayer |
7
|